PlainRecalls
FDA Drug Moderate Class II Terminated

Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83

Reported: July 19, 2023 Initiated: July 10, 2023 #D-0914-2023

Product Description

Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83

Reason for Recall

Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing

Details

Units Affected
8,880 30-count bottles
Distribution
Distributed nationwide in the USA.
Location
Princeton, NJ

Frequently Asked Questions

What product was recalled?
Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83. Recalled by SUN PHARMACEUTICAL INDUSTRIES INC. Units affected: 8,880 30-count bottles.
Why was this product recalled?
Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing
Which agency issued this recall?
This recall was issued by the FDA Drug on July 19, 2023. Severity: Moderate. Recall number: D-0914-2023.